Ceftazidime inhibits bacterial cell-wall synthesis by binding to penicillin-binding proteins. Avibactam inhibits several beta-lactamase enzymes that can otherwise degrade beta-lactam antibiotics, thereby helping protect the antibacterial activity of ceftazidime.
How it works
Who may be prescribed this medicine
The product is used under medical supervision for serious or complicated bacterial infections when the causative organism is susceptible to ceftazidime/avibactam. Microbiological culture and susceptibility testing should be considered when available.
Research and clinical evidence
Ceftazidime/avibactam has been evaluated in clinical studies involving complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired or ventilator-associated pneumonia. These studies contributed to the established therapeutic indications for the combination. Current prescribing information includes dedicated clinical-study sections for these infection types.
The European Medicines Agency classifies the combination as a systemic antibacterial medicine and recognizes its use for complicated intra-abdominal and urinary tract infections, as well as hospital-acquired and ventilator-associated pneumonia.
The medicine is not effective against viral infections. To reduce the development of antimicrobial resistance, it should be used only when a susceptible bacterial infection is confirmed or strongly suspected.
Ceftazidime/avibactam is used for the treatment of:
For complicated intra-abdominal infections, ceftazidime/avibactam is administered together with metronidazole to provide appropriate coverage against anaerobic organisms.
The product is intended for intravenous administration after reconstitution of the sterile powder. The dose, dosing interval, and treatment duration are determined by a healthcare professional based on the type and severity of infection, age, and kidney function. Dose adjustment is required in patients with renal impairment. For adults with normal renal function, the labeled regimen is 2.5 g every 8 hours administered by intravenous infusion over 2 hours; this information does not replace individualized medical prescribing.
